A reduction in brain pathology has been observed in a mouse model of TSC2 given intravenous AAV gene therapy [66], and a landmark study that generated a human organoid model for TSC and identified caudal late interneuron progenitor (CLIP) cells [67] has furthered our understanding of brain development in patients with TSC. The gene discussed is TSC2; the disease is tuberous sclerosis.